12 Month Price Forecast For EVGN
Distance to EVGN Price Forecasts
EVGN Price Momentum
๐ค Considering Evogene (EVGN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 5, 2025 11:50 PM UTC
EVGN Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, EVGN has a consensus that is bullish. The median price target is $8.13, with forecasts ranging from $5.00 to $11.25. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With EVGN currently trading at $1.47, the median price forecast suggests a 452.7% upside. The most optimistic forecast comes from at , projecting a 665.3% upside, while at provides the most conservative target, suggesting a 240.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVGN Analyst Consensus
EVGN Price Target Range
Latest EVGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVGN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Aug 23, 2024 | Lake Street | Ben Klieve | Buy | Maintains | $12.00 |
Oct 2, 2023 | Alliance Global Partners | Ben Haynor | Buy | Initiates | $1.85 |
Aug 18, 2023 | Lake Street | Ben Klieve | Buy | Maintains | $3.00 |
Jul 21, 2023 | Roth MKM | Buy | Maintains | $0.00 | |
May 2, 2023 | Lake Street | Ben Klieve | Buy | Initiates | $2.00 |
Sep 12, 2022 | Aegis Capital | Nathan Weinstein | Buy | Maintains | $8.00 |
Sep 2, 2022 | Roth MKM | Buy | Maintains | $0.00 | |
Oct 8, 2021 | Roth Capital | Brian Wright | Buy | Initiates | $7.00 |
Jul 29, 2021 | Aegis Capital | Buy | Initiates | $0.00 | |
Dec 1, 2020 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
Nov 12, 2014 | Credit Suisse | Outperform | Maintains | $22.00 | |
Dec 17, 2013 | Deutsche Bank | Buy | Initiates | $0.00 | |
Dec 16, 2013 | Credit Suisse | Outperform | Initiates | $0.00 |
Stocks Similar to Evogene Ltd
The following stocks are similar to Evogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Evogene Ltd (EVGN) Financial Data
Evogene Ltd has a market capitalization of $9.73M with a P/E ratio of 0.3x. The company generates $9.45M in trailing twelve-month revenue with a -210.3% profit margin.
Revenue growth is +39.8% quarter-over-quarter, while maintaining an operating margin of -667.1% and return on equity of -82.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Evogene Ltd (EVGN) Company Overview
About Evogene Ltd
Operates as a computational biology company.
The company utilizes its Computational Predictive Biology (CPB) platform to drive product discovery and development across three main segments: Agriculture, Human Health, and Industrial Applications. It generates revenue by developing innovative seed traits, ag-chemical products, and therapeutics, as well as providing medical cannabis products.
Founded in 1999 and headquartered in Rehovot, Israel, Evogene Ltd. operates internationally in markets such as the United States, Brazil, and more. The company's focus on enhancing plant performance and developing human microbiome-based therapeutics positions it well within the growing life-science industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
142
CEO
Mr. Ofer Haviv CPA
Country
Israel
IPO Year
2010
Website
www.evogene.comEvogene Ltd (EVGN) Latest News & Analysis
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
2 months agoEvogene Ltd. (NASDAQ:EVGN) will hold its Q3 2024 earnings conference call on November 21, 2024, at 9:00 AM ET, featuring key company executives.
Evogene's Q3 earnings call indicates upcoming financial performance insights, impacting stock valuation and investor sentiment based on growth or challenges revealed.
Evogene Reports Third Quarter 2024 Financial Results
2 months agoFor the first nine months of 2024, revenues were $6.9M, up from $5.1M in 2023. Q3 2024 revenues were $1.8M, down from $3.8M in Q3 2023.
The revenue growth in the first nine months signals positive performance, but the significant drop in Q3 raises concerns about sustainability and potential market challenges.
Lavie Bio Ltd. reported strong results from its third consecutive year of field trials in Europe, highlighting its progress in ag-biologicals.
Strong trial results for LAV321 enhance Lavie Bio's market position and growth potential, potentially boosting investor confidence and stock performance in the ag-biologicals sector.
Lavie Bio Announces Commercial Expansion of Yalosยฎ as Seed-Treatment for Soybean, Following Successful Field Trials
2 months agoLavie Bio plans to start sales of its Yalosยฎ soybean product in the spring of 2025, as announced on November 12, 2024.
Yalosยฎ sales starting in spring 2025 could boost Lavie Bio's revenues and market position, influencing stock performance and investor sentiment in the ag-biological sector.
Evogene Ltd. will release its Q3 2024 financial results on November 21, 2024, at 9:00 AM ET, and will hold a conference call to discuss the results.
The upcoming earnings call could reveal key financial insights and strategic developments for Evogene Ltd., influencing investor sentiment and stock performance.
Casterra Ag Ltd. delivered over 100 tons of castor oil to a customer in Africa, enhancing its role in bio-based products and biofuel production.
The shipment indicates strong demand for Casterra's products, signaling potential revenue growth and market expansion, which could positively impact stock performance and investor sentiment.
Frequently Asked Questions About EVGN Stock
What is Evogene Ltd's (EVGN) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Evogene Ltd (EVGN) has a median price target of $8.13. The highest price target is $11.25 and the lowest is $5.00.
Is EVGN stock a good investment in 2025?
According to current analyst ratings, EVGN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for EVGN stock?
Wall Street analysts predict EVGN stock could reach $8.13 in the next 12 months. This represents a 452.7% increase from the current price of $1.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evogene Ltd's business model?
The company utilizes its Computational Predictive Biology (CPB) platform to drive product discovery and development across three main segments: Agriculture, Human Health, and Industrial Applications. It generates revenue by developing innovative seed traits, ag-chemical products, and therapeutics, as well as providing medical cannabis products.
What is the highest forecasted price for EVGN Evogene Ltd?
The highest price target for EVGN is $11.25 from at , which represents a 665.3% increase from the current price of $1.47.
What is the lowest forecasted price for EVGN Evogene Ltd?
The lowest price target for EVGN is $5.00 from at , which represents a 240.1% increase from the current price of $1.47.
What is the overall EVGN consensus from analysts for Evogene Ltd?
The overall analyst consensus for EVGN is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.13.
How accurate are EVGN stock price projections?
Stock price projections, including those for Evogene Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.